What 4E Therapeutics does

4E Therapeutics is a neuroscience drug development company founded in 2019 in Austin, Texas, focused on non-opioid treatments for chronic neuropathic pain and related pain disorders. The company's scientific premise is that MNK-mediated phosphorylation of eIF4E is the final common pathway linking injury to nociceptor plasticity that drives chronic pain, and that inhibiting this pathway in peripheral sensory neurons can suppress pain signal generation without the central nervous system side effects and addiction risk associated with opioid analgesics. Its core technology is a proprietary library of more than 150 small molecule MNK inhibitors, optimized through medicinal chemistry to be peripherally-restricted and orally bioavailable, with three named programs: 4ET1103 (lead neuropathic pain compound, completed Phase 1 with a favorable safety profile and demonstrated target engagement in human dorsal root ganglion neurons), 4ET2124 (clinical candidate for migraine, IND-enabling stage, with 4ET2104 as backup), and an earlier-stage acute pain program.

The company was led by CEO T. Craig Benson (since February 2020), co-founders Ted Price (Ashbel Smith Professor and Director of the Center for Advanced Pain Studies at UT Dallas) and Joe Price (President and Chairman), with a small executive team including a CMO with deep clinical pain research credentials. 4E operated as a lean, virtually-structured biotechnology company funded primarily through a $5.5 million NIH Phase 2 SBIR grant awarded in November 2021 under the NIH HEAL Initiative, plus prior NIH funding and undisclosed private capital (total disclosed funding approximately $10 million). The company had 11–50 employees and no commercial revenue; its business model was asset-based pharmaceutical R&D dependent on future licensing, partnership, or acquisition monetization. In June 2026, Eli Lilly acquired 4E Therapeutics for an undisclosed sum, absorbing its pipeline into Lilly's non-opioid pain portfolio as part of an aggressive early-stage neuroscience M&A push.

Name

4E Therapeutics

Legal name

4E Therapeutics Inc

Website

https://4etherapeutics.com

Company type

Private

Founded year

2019

Operating status

Acquired

Headcount range

11–50 employees

Short description

4E Therapeutics is an Austin, Texas-based neuroscience drug developer (founded 2019) creating peripherally-restricted, orally-bioavailable small molecule MNK inhibitors for chronic neuropathic pain, migraine, and acute pain, acquired by Eli Lilly in June 2026.

Ownership category

akta.pro rank

Product category

Pain Management Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN)

akta.pro secondary industries

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Pain Medicine (Interventional/Neuropathic Pain) (HLAKAIAM), Headache & Migraine Medicine (HLAKAIAE), In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy) (HLAAAIAK)

Keywords

• Neuropathic pain therapeutics
• MNK inhibitor development
• Non-opioid pain medications
• Small molecule drug discovery
• Clinical stage biotechnology

Headquarters

HQ city

Austin

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Others

Core offering

4E Therapeutics is a neuroscience company developing a pipeline of peripherally-restricted, orally-bioavailable small molecule MNK inhibitors that target the MNK-eIF4E signaling pathway for the treatment of neuropathic pain, migraine, and acute pain. The portfolio includes lead compound 4ET1103 (Phase 1 completed for neuropathic pain), clinical candidate 4ET2124 (migraine), backup 4ET2104 (migraine), and a discovery-stage acute pain program. The compounds are designed to avoid central nervous system side effects common in existing pain therapeutics.

Product overview

4E Therapeutics is a neuroscience company developing a pipeline of non-opioid therapeutic assets targeting the MNK-eIF4E signaling pathway for pain treatment. The company's portfolio includes three clinical-stage programs: 4ET1103 (lead compound for neuropathic pain, completed Phase 1), 4ET2124 (clinical candidate for migraine), and 4ET2104 (backup for migraine), along with a discovery-stage acute pain program. All candidates are peripherally-restricted, orally-bioavailable small molecule MNK inhibitors designed to avoid CNS side effects common in existing therapeutics.

Differentiator

Problem solved

Functional benefit

Products and services

• 4ET1103 Lead compound for neuropathic pain; peripherally-restricted, orally-bioavailable small molecule MNK inhibitor that demonstrated favorable safety profile in Phase 1 studies and blocked evoked MNK activity in human dorsal root ganglion neurons. IND-enabling studies completed.
• 4ET2124 Clinical candidate selected for migraine pain treatment; small molecule MNK inhibitor with excellent in vitro safety profile and efficacy across multiple animal models of migraine.
• 4ET2104 Backup compound for migraine; small molecule MNK inhibitor positioned as backup to 4ET2124, with excellent in vitro safety profile and efficacy across multiple animal models of migraine.
• MNK-eIF4E Inhibitor Program (Acute Pain) Peripherally-restricted small molecule MNK inhibitors targeting the MNK-eIF4E signaling pathway for acute pain treatment; non-brain penetrant compounds designed to avoid central-nervous-system side effects. Discovery stage.

Quantifiable outcome

• 4ET1103 blocked evoked MNK activity in human dorsal root ganglion neurons from organ donors, demonstrating translational potential
• +1 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Eli Lilly and CompanyflagshipOthers · 16 June 2026Eli Lilly acquired 4E Therapeutics for an undisclosed sum as part of an aggressive M&A strategy targeting early-stage assets across neuroscience. The acquisition brings 4E's pipeline of oral MNK inhibitor medications for chronic pain under Lilly's clinical development and global commercial capabilities. This was Lilly's 11th acquisition announced in 2026.

Scale indicators4 records

Recent moves7 records

Expansion highlights4 records

Broad incumbents

• Pfizer: Major pharma with a chronic pain portfolio (including tanezumab, an anti-NGF therapy); competes broadly in the non-opioid pain therapeutics space with established commercial capabilities.
• AbbVie: Through Allergan, AbbVie markets several pain therapeutics and is pursuing novel non-opioid pain assets, making it a broad incumbent competitor in chronic and neuropathic pain.
• Regeneron Pharmaceuticals: Major biotech with a pain portfolio including fasinumab (anti-NGF) and broad neuroscience capabilities; relevant broad incumbent competitor in non-opioid pain therapeutics.
• Acadia Pharmaceuticals: Acquired CerSci Therapeutics (co-founded by 4E co-founder Ted Price) in 2020, positioning Acadia as a peer in the non-opioid neuropathic pain space and validating the same scientific founder's prior work.
• Eli Lilly and Company: Acquirer of 4E Therapeutics and a major pharma with a broad pain and neuroscience portfolio; comparable as the strategic acquirer validating and now developing 4E's MNK inhibitor assets.

Direct peers

• Vertex Pharmaceuticals: Vertex's NaV1.8 inhibitor suzetrigine (VX-548) is a leading non-opioid acute pain therapeutic approved by FDA, making Vertex the most directly comparable pain biotech pursuing novel-mechanism, non-opioid analgesia.
• Biohaven Pharmaceuticals: Specializes in migraine and neuroscience therapeutics (CGRP receptor antagonists such as rimegepant/Nurtec); directly relevant peer given 4E's migraine program 4ET2124.

Emerging players

• Latigo Biotherapeutics: Clinical-stage biotech developing non-opioid pain therapeutics targeting NaV1.8 and related ion channels; comparable as an emerging player pursuing novel mechanism pain drugs.
• Tonix Pharmaceuticals: Clinical-stage biotech with non-opioid pain programs, including TNX-102 SL for fibromyalgia; comparable as an emerging player in non-opioid pain therapeutic development.
• Aptinyx: Clinical-stage biotech developing NMDA receptor modulators for chronic pain and CNS disorders; comparable as an emerging player pursuing novel mechanism pain therapeutics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/4e-therapeutics-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 4E Therapeutics